More recently, a study showed that a peptide vaccine that is specific to HLA-A*02:01 and HLA-B*07:02 could prime ALK-specific CD8+ T cells to generate an immune response to ALK+ NSCLC tumors that current ALK inhibition with TKI cannot[142]. This evidence concerns the gene ALK and non-small cell lung carcinoma.